Invest Today In EARLY-STAGE 

SHARES 

SOON TO BE FULLY QUALIFIED 

SECURITIES & EXCHANGE

OFFERING

$1.00 PER SHARE

Cannabis consumers globally spent an estimated $415 billion on high-THC cannabis in 2020, with annual spending projected to climb to $496 billion by 2025.

WHAT IS TISSUE CULTURE?

Tissue culture is a method of growing new plants from tiny pieces of a plant, like a leaf or stem, in a special nutrient-rich gel. Think of it like planting seeds, but instead of seeds, we're using small plant parts. This allows us to grow many new plants that are exact copies of the original.

Why is Tissue Culture the Future of Cannabis?

• Healthier Plants: Tissue culture helps us grow plants that are free from diseases and pests, leading to healthier crops.

Consistent Quality: Every plant grown from tissue culture is a clone, meaning they are all the same. This ensures consistent quality and potency in cannabis products.

Faster Growth: Plants grown from tissue culture can grow faster and stronger, leading to quicker harvests.

Space-Saving: We can grow many plants in a small space using tissue culture, making it more efficient and cost-effective.

Preserving Genetics: Tissue culture allows us to preserve the genetic makeup of a plant, ensuring that rare or valuable strains are not lost.

Why not just use seeds? When you grow plants from seeds, each seed can produce a plant that's a bit different from the others. This means the plants can vary in size, strength, and quality. With tissue culture, we avoid this inconsistency because all the plants are an exact clone, giving us uniform and predictable results.

In short, tissue culture helps us grow better, healthier, and more consistent cannabis plants, making it a promising method for the future of cannabis cultivation.

Most recent estimates, approximately 219 million individuals across the globe are reported to engage in the consumption and use of cannabis.

The Endless Data Driven Approach

By leveraging the power of data analytics and scientific instrumentation, the Endless team is continuously pushing the boundaries of knowledge in cannabis cultivation, paving the way for achieving maximum success in producing premium quality pharmaceutical grade cannabis plants through tissue culture technology. Once final results are recorded the data is compiled and shared with our clients positioning them for the highest possibility of success.

THE ENDLESS DIFFERENCE

INDUSTRY AVERAGE

THC: 15% - 25%
Terp Profile: 1.8% - 2.1%
Production of Flower: 55 grams/sqft

ENDLESS AVERAGE

THC: 28% - 34%
Terp Profile: 3.5% - 5.8%
Production of Flower: 115 - 120 grams/sqft


MEET THE ENDLESS BIOTECH TEAM

The Endless team is highly recognized for their science and biology background as well as their passion for revolutionizing the cannabis industry through cutting-edge tissue culture technology.  

Our team includes top researchers, biotechnologists, PHD biochemist and a Nuclear Scientist leading the team who bring a wealth of knowledge and experience to the table. Each member has been carefully selected for their unique skills and contributions to advancing our mission of producing high-quality, genetically consistent cannabis plants at scale.

TRAVIS DAHM

CHIEF EXECUTIVE OFFICER
International Finance

GARY HOLLAND

PRESIDENT, CHIEF OPERATING OFFICER
Nuclear Scientist & Engineer

BRAZ VAIDYA

CHIEF SCIENTIST
World Renowned Plant Scientist

TIM LOZOTT

CHIEF FINANCIAL OFFICER
Capital Markets

COURTNEY BRIDGES

PLANT HEALTH & ANALYTICS
Bio-infomatics & Biologist

ENDLESS BIOTECH'S GLOBAL STRATEGIC PARTNERS

Endless has strategically partnered with leading industry innovators in the cannabis cultivation market. 

Through collaborative efforts with our partners, Endless Biotech is actively engaged in targeting a global audience through collective strategic marketing initiatives. By aligning our marketing efforts with the expertise and reach of Fohse, Athena, Grodan, PIPP, and Quest, we aim to amplify our brand visibility and engage with potential customers on a global scale. Leveraging the established books of business of our partners, we can effectively tap into new markets, introduce our innovative solutions to a wider audience, and foster strong relationships with clients worldwide.

This synchronized approach to marketing not only enhances our market reach but also strengthens our position as a key player in the cannabis cultivation industry. By combining our resources, knowledge, and networks, we can create impactful marketing campaigns that resonate with diverse audiences, drive brand awareness, and ultimately support our mutual goal of expanding our global footprint and driving collective revenue growth.

TOP REASONS TO CONSIDER OWNING ENDLESS STOCK

#1

ENDLESS WELCOMES BRAZ VAIDYA AS CHIEF SCIENTIST

A career spanning over two decades and experience in both national and international projects, with Braz on board, we are poised to meet our ambitious goal of producing 5,000,000 tissue culture clones per month. His expertise in tissue culture and plant biotechnology is exactly what we need to achieve this milestone and continue leading the industry in innovation and growth.

#2

ENDLESS TO LAUNCH FIRST REG A+ $75 MILLION STOCK OFFERING CAPITAL RAISE


Endless is launching the 1st of 3 intended REG A+ $75 Million Capital Raises setting the stage for an anticipated 2027-2028 year end direct listing or Full S-1 Registration Initial Public Offering (IPO) onto the Nasdaq Stock Exchange.

#3

ENDLESS CORP SECURES A THREE (3) YEAR $11 MILLION FLOWER CONTRACT


A Licensed Medical Cannabis Operator who is now contracted to purchase & grow distribution of Endless's Tissue Culture Flower & Clones to dispensaries and grow operations.

This strategic partnership will grow the Endless Brand. In alliance, a strategic co-branding campaign of Conte TM Retail Packaged Flower will include "Powered by Endless" on all retail packaging.

#4

71 COUNTRIES HAVE ADOPTED CANNABIS LEGALIZATION


The global cannabis market has experienced substantial growth, with estimates suggesting it has reached hundreds of billions of dollars annually. As nation continue to legalize the consumption and distributions of cannabis for both pharmaceutical and recreational use, demand for pharmaceutical grade genetics is exploding. The global cannabis market size is projected to grow from $57.18 billion in 2023 to $444.34 billion by 2030, at a CAGR of 34.03% during the forecast period. North America dominated the Global Market with a share of 81.79% in 2022.

#5

$120 MILLION OF GLOBAL LEADS IN THE PIPELINE


Endless is currently working with grow operations across the world. Our pipeline of leads for both traditional clones and tissue culture could generate as much $120mm in annualized revenues. Endless is consistently receiving sales calls and leads from countries located across the globe desiring Endless's Tissue Culture & Clones

#6

ENDLESS CAN SELL AND DISTRIBUTE ITS CANNABIS TISSUE CULTURES & CLONES WORLDWIDE


What truly sets Endless Biotech apart in the expanding global cannabis market is its ability to sell and distribute tissue cultures and clones to any grow operation worldwide. This is possible because Endless's tissue cultures and clones contain no THC at the point of sale, thanks to the plants' immaturity.

OFFICIAL SECURITIES & EXCHANGE QUALIFIED OFFERING

$1.00 PER SHARE

(Minimum 1,000 shares)
REG A+ "Regulation A" Stock Offering

RESERVE YOUR SHARES NOW

HAVE QUESTIONS? CALL (918) 486-9451.

PARTNER TESTIMONIALS

What Our Strategic Partners Are Saying